Shared on 25 Mar 26

Fair value Increased 18%

COPN: Higher Revenue Assumptions And Single Investor Placement Will Support Upside

Analysts have lifted their price target on Cosmo Pharmaceuticals from CHF 104.55 to around CHF 123.72, reflecting updated assumptions for higher revenue growth, a different profit margin profile, and a higher future P/E multiple. What's in the News Cosmo Pharmaceuticals completed a private placement with a single institutional investor, issuing 937,086 treasury shares that represent 5.3% of the company's outstanding shares as of February 3, 2026 (Key Developments).

12 views

Shared on 26 Jan 26

Fair value Increased 6.92%

COPN: EU Acne Launch And Margin Assumptions Will Likely Keep Shares Fairly Valued

Analysts have moderately raised their price target on Cosmo Pharmaceuticals, citing updates to their fair value estimate along with revised assumptions for revenue growth, profit margins and future P/E. What's in the News The European Commission granted Marketing Authorization for Winlevi (clascoterone 10 mg/g cream) following a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use issued on August 25, 2025 (Key Developments).

23 views

Shared on 11 Jan 26

Fair value Decreased 0.47%

COPN: EU Acne Authorization And Rollout Will Likely Leave Shares Overextended

Analysts have trimmed their price target for Cosmo Pharmaceuticals by roughly €0.46, reflecting slightly lower assumptions for revenue growth and profit margins, along with a higher future P/E multiple in their updated models. What's in the News The European Commission granted Marketing Authorization for Winlevi (clascoterone 10 mg/g cream), following a prior positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use issued on August 25, 2025 (Key Developments).

19 views

Shared on 24 Dec 25

Fair value Decreased 0.49%

COPN: EU Acne Approval And Rollout Are Expected To Support Balanced Outlook

Analysts have modestly trimmed their price target for Cosmo Pharmaceuticals by approximately $0.48, reflecting refined assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News European Commission grants Marketing Authorization for Winlevi clascoterone 10 mg/g cream for the treatment of acne vulgaris in adults and adolescents 12 to under 18 years, with adolescent use limited to facial application only Key Developments Cosmo Pharmaceuticals and Glenmark Pharmaceuticals secure EU wide approval enabling commercialization of Winlevi across 15 countries, including France, Spain, the Netherlands, and the Nordics Key Developments Glenmark prepares to launch Winlevi in a staged rollout across Bulgaria, the Czech Republic, Denmark, Finland, Hungary, Iceland, Norway, Poland, Portugal, Romania, Slovakia, Sweden, and other approved EU markets Key Developments Valuation Changes The Fair Value Estimate has fallen slightly to CHF 98.24 from CHF 98.72, reflecting a modest downward adjustment in intrinsic valuation.

15 views

Shared on 09 Dec 25

Fair value Increased 0.13%

COPN: EU Authorization And Launch Partnership Are Expected To Support Balanced Outlook

Analysts have nudged their price target for Cosmo Pharmaceuticals slightly higher to approximately $98.72 per share from about $98.59, citing expectations for stronger revenue growth that more than offset a modestly lower projected profit margin and valuation multiple. What's in the News European Commission grants Marketing Authorization for Winlevi clascoterone 10 mg/g cream for treatment of acne vulgaris in adults and adolescents aged 12 to under 18 years, with adolescent use restricted to facial application EU Marketing Authorization Approval follows a positive CHMP opinion issued on August 25, 2025, confirming regulatory momentum for Cosmo Pharmaceuticals dermatology portfolio EU Marketing Authorization Commercial launch of Winlevi to be led by partner Glenmark Pharmaceuticals across 15 European countries, including France, Spain, the Netherlands, and the Nordics, expanding Cosmo Pharmaceuticals geographic reach EU Marketing Authorization Valuation Changes Fair Value Estimate has risen slightly to CHF 98.72 from CHF 98.59 per share, reflecting a marginal upward revision to intrinsic value.

9 views

Shared on 25 Nov 25

Fair value Increased 12%

COPN: EU Approval And Expanded Distribution Expected To Drive Share Performance

Analysts have raised their price target for Cosmo Pharmaceuticals from $87.81 to $98.59. They cite updated fair value assessments and recent model adjustments as the reasons for the change.

47 views

Shared on 04 Sep 25

Fair value Decreased 0.63%

Cosmo Pharmaceuticals’ consensus revenue growth forecasts have strengthened and its future P/E valuation has decreased, but despite these more favourable fundamentals, the consensus analyst price target was only marginally reduced from CHF88.37 to CHF87.81. What's in the News Issued FY2025 guidance: total revenues expected between EUR 102 million and EUR 107 million, with recurring revenues of EUR 85 million to EUR 90 million and project-based revenues of EUR 17 million.

16 views

Shared on 09 Apr 25

Fair value Decreased 6.64%

2 views

Shared on 02 Apr 25

Fair value Decreased 2.96%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

2 views

Shared on 26 Mar 25

Fair value Decreased 1.44%

AnalystConsensusTarget has decreased revenue growth from 12.8% to 6.9%, increased profit margin from 74.7% to 87.4% and decreased future PE multiple from 9.9x to 6.5x.

0 views

Shared on 19 Mar 25

Fair value Decreased 2.69%

0 views

Expanding AI Diagnostics And Drug Platforms Will Navigate Regulatory Challenges

COPN: Higher Revenue Assumptions And Single Investor Placement Will Support Upside

COPN: EU Acne Launch And Margin Assumptions Will Likely Keep Shares Fairly Valued

COPN: EU Acne Authorization And Rollout Will Likely Leave Shares Overextended

COPN: EU Acne Approval And Rollout Are Expected To Support Balanced Outlook

COPN: EU Authorization And Launch Partnership Are Expected To Support Balanced Outlook

COPN: EU Approval And Expanded Distribution Expected To Drive Share Performance

Shared on 04 Sep 25

Shared on 09 Apr 25

Shared on 02 Apr 25

Shared on 26 Mar 25

Shared on 19 Mar 25

Fair Value vs Share Price

Recent News & Updates

Recent updates

Stay ahead on Cosmo

Company analysis

CEO & management